August 22, 2023
Precision Medicine Online's Risk Stratification Section
PreciseDx Begins Limited Rollout of ‘Quantitative’ Test for Grading Invasive Breast Cancer
Focused on Changing Breast Cancer Outcomes
PreciseDx is dedicated to supporting more personalized and precise treatments for breast cancer.
On average, every two minutes a woman is diagnosed with breast cancer in the United States.
About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.
About PreciseDx
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.
Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists
Better Data. Better Outcomes.
PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.
- Patients
- Providers
- Payers
- BioPharma
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Patients
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
Providers
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
Payers
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
BioPharma
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Corporate Council Member of
The National Comprehensive Cancer Network® (NCCN®)
Jack Zeineh, PreciseDx
Corporate Council Member of
The National Comprehensive Cancer Network® (NCCN®)
Featured Resources & Media
Media Coverage
Media Coverage
July 24, 2023
Valint CEO magazine
AI-Powered Precision: Wayne Brinster and the Revolutionary Future of Disease Analysis at PreciseDx
Media Coverage
Media Coverage
Media Coverage
Press Release
June 27, 2023
PR Newswire
PreciseDx Announces Ted Diehl as Vice President of Commercial Development
Media Coverage
August 22, 2023
Precision Medicine Online's Risk Stratification Section
PreciseDx Begins Limited Rollout of ‘Quantitative’ Test for Grading Invasive Breast Cancer
Media Coverage
July 24, 2023
Valint CEO magazine
AI-Powered Precision: Wayne Brinster and the Revolutionary Future of Disease Analysis at PreciseDx
Media Coverage